Article
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.
Cancer - 1 Jul 2026
Huang Shiwang, Jia Kaipeng, Liang Shan, Ma Boyue, Chen Huitong, Zhang Zhe, Kang Ning, Wu Zhouliang, Lin Yuda, Li Peng, Xue Zihan, Chen Houyuan, Zhao Yang, Guo Jianing, Li Changping, Chai Wang, Cui Jingmin, Xu Guoping, Qie Yunkai, Shen Chong, Hu Hailong
Abstract excerpt
BACKGROUND: Patients with very high-risk (VHR), nonmuscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy face limited treatment options. Immune checkpoint inhibitor-based regimens have demonstrated promise but lack reliable biomarkers to guide patient selection. The objective of this study was to identify magnetic resonance imaging-derived radiomic phenotypes predictive of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.